Daiichi Sankyo is the second largest pharma company in Japan, developing small molecules & biologics for various diseases and was came into existence in 2005, through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
- In Jan 2021, Daiichi Sankyo files for New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for teserpaturev (G47∆), an oncolytic virus, for the treatment of patients with malignant glioma.
- In Jan 2021, the US FDA approved fam-trastuzumab deruxtecan-nxki (ENHERTU®, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
- In Dec 2020, the US FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU®, Daiichi Sankyo) for patients with Unresistable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
- In Aug 2019, the US FDA approved Turalio (pexidartinib), an oral small molecule tyrosine kinase inhibitor (TKI) indicated as a treatment for symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
- In June 2019, Japan’s Ministry of Health, Labor and Welfare (MHLW) approved FLT3 Inhibitor VANFLYTA® (quizartinib) in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD acute myeloid leukemia (AML).
- Vemurafenib/Zelboraf™ (developed by Plexxikon in collaboration with Roche) is FDA approved for the treatment of Unresistable or metastatic melanoma (for further details see Plexxikon).
Page 1 of 2
